Amedeo's Top 20

Amedeo Smart

Independent Medical Education

20 November 2023

Multidisciplinary Journal Club

  1. Heerspink HJL, Kiyosue A, Wheeler DC, Lin M, et al.
    Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.
    Lancet 2023.

  1. Friedman HS, Prados MD, Wen PY, Mikkelsen T, et al.
    Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma.
    J Clin Oncol 2023;41:4945-4952.

  2. .
    Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials.
    Lancet 2023.

  3. Poespoprodjo JR, Douglas NM, Ansong D, Kho S, et al.
    Malaria.
    Lancet 2023.

  4. Taber-Hight E, Gilmore A, Friedman AN.
    Antiobesity Pharmacotherapy in Adults with Chronic Kidney Disease.
    Kidney Int 2023.

  1. Xu Y, Chang AR, Inker LA, McAdams-DeMarco M, et al.
    Associations of Apixaban Dose With Safety and Effectiveness Outcomes in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease.
    Circulation 2023.

  2. Pittock RR, Aakre JA, Castillo AM, Ramanan VK, et al.
    Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
    Neurology 2023;101:e1837-e1849.

  3. Bidard FC, Kiavue N, Jacot W, Bachelot T, et al.
    Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial.
    J Clin Oncol 2023.

  4. Thiebaut AM, Louet ER, Ianszen M, Guichard MJ, et al.
    O2L-001, an innovative thrombolytic to evacuate intracerebral haematoma.
    Brain 2023.

  5. Selinger S.
    In adults with HIV and low-to-moderate CV risk, pitavastatin reduced MACE over a median 5.1 y.
    Ann Intern Med 2023.

  1. Nakashima A, Miyawaki Y, Komaba H, Kurita N, et al.
    Proton pump inhibitors and hyporesponsiveness to erythropoiesis stimulating agents in hemodialysis patients: results from the Japan Dialysis Outcomes and Practice Patterns Study.
    Am J Nephrol 2023.

  2. Kulkarni AV, Avadhanam M, Karandikar P, Rakam K, et al.
    Antibiotics with or without Rifaximin for acute hepatic Encephalopathy in critically ill patients with cirrhosis: A double-blind, randomized controlled (ARiE) trial.
    Am J Gastroenterol 2023.

  3. Hill PC, Cobelens F, Martinez L, Behr MA, et al.
    An aspiration to radically shorten phase 3 TB vaccine trials.
    J Infect Dis 2023.

  4. Berg KM, Bray JE, Ng KC, Liley HG, et al.
    2023 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations: Summary From the Basic Life Support; Advanced Life Support; Pediatric Life Support; Neonatal Life Sup
    Circulation 2023.

  5. Caspi A, Shireby G, Mill J, Moffitt TE, et al.
    Accelerated pace of aging in schizophrenia: Five case-control studies.
    Biol Psychiatry 2023.

  1. de Munck L, Eijkelboom AH, Otten JDM, Broeders MJM, et al.
    Method of primary breast cancer detection and the disease-free interval, adjusting for lead time.
    J Natl Cancer Inst 2023.

  2. Bosco K, Lynch S, Sandaradura I, Khatami A, et al.
    Therapeutic Phage Monitoring: A Review.
    Clin Infect Dis 2023;77:S384-S394.

  3. Douglas RS, Couch S, Wester ST, Fowler BT, et al.
    Efficacy and Safety of Teprotumumab in Thyroid Eye Disease Patients with Long Duration and Low Disease Activity.
    J Clin Endocrinol Metab 2023.

  4. Miszczyk M, Rajwa P, Yanagisawa T, Nowicka Z, et al.
    The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies.
    Eur Urol 2023.

  5. Khan SS, Matsushita K, Sang Y, Ballew SH, et al.
    Development and Validation of the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations.
    Circulation 2023.


more..

Privacy Policy